p53 peptide–MHC class I complex

The p53 peptide–MHC class I complex is a molecular structure resulting from the binding of peptides derived from the p53 protein — especially those generated by tumor-specific mutations (neoantigens) or overexpressed wild-type p53 — to class I major histocompatibility complex (MHC) molecules, such as HLA-A2 or HLA-A24. This complex is presented on the surface of cells, particularly tumor cells, and is recognized by the T cell receptor (TCR) of cytotoxic CD8^+^ T lymphocytes, triggering immune-mediated elimination of abnormal cells[5][7]. Therapeutically, this complex is an attractive target for engineered T cell receptors, TCR mimic antibodies, and antibody-drug conjugates as it enables selective targeting of cancer cells with minimal direct effect on healthy tissue, although safety concerns due to shared peptide sequences must be critically evaluated[5][6][7]. The specificity of the immune recognition depends on the exact peptide sequence and the presenting MHC allele; therapeutics in this area are often highly allele- and peptide-specific. This target is correctly defined, is an important focus in modern immuno-oncology, and is actively under study for cancer immunotherapy in both T cell– and antibody-based modalities[5][7].

Other names

p53-derived peptide–MHC class I complexp53 peptide–HLA complexp53 peptide–HLA-A2 (or other specific HLA types, e.g., HLA-A24)p53 neoantigen–MHC complex

Recognition by cytotoxic T lymphocytes (CTLs) via T cell receptor (TCR) leading to targeted killing of peptide-presenting tumor cells[5][7] Engagement by TCR mimic antibodies (TCRm), enabling antibody-dependent cellular cytotoxicity (ADCC) or targeted delivery of cytotoxic payloads[5][6]